Get the Stockscreener App
9.18
0.88%
+0.08
After Hours:
9.18
Phathom Pharmaceuticals Inc stock is currently priced at $9.18, with a 24-hour trading volume of 365.64K.
It has seen a +0.88% increased in the last 24 hours and a -12.57% declined in the past month.
The chart indicates a potential bullish trend, as the stock is above the $9.07 pivot point. If it approaches the $9.39 resistance level, significant changes may occur.
Previous Close:
$9.10
Open:
$9.08
24h Volume:
365.64K
Market Cap:
$537.25M
Revenue:
-
Net Income/Loss:
$-201.59M
P/E Ratio:
-2.0959
EPS:
-4.38
Net Cash Flow:
$-139.21M
1W Performance:
+2.34%
1M Performance:
-12.57%
6M Performance:
+7.75%
1Y Performance:
-10.09%
1D Range:
$8.96
$9.43
52W Range:
$6.065
$17.02
Phathom Pharmaceuticals Inc Stock (PHAT) Company Profile
Name
Phathom Pharmaceuticals Inc
Sector
Industry
Phone
877 742 8466
Address
100 Campus Drive, Suite 102, Florham Park, NJ
Phathom Pharmaceuticals Inc Stock (PHAT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-09-23 | Initiated | H.C. Wainwright | Buy |
| May-11-23 | Upgrade | Evercore ISI | In-line → Outperform |
| Mar-13-23 | Initiated | Craig Hallum | Buy |
| Oct-21-22 | Initiated | Jefferies | Buy |
| May-06-22 | Downgrade | Evercore ISI | Outperform → In-line |
| May-12-21 | Upgrade | Goldman | Sell → Neutral |
| Feb-17-21 | Initiated | BMO Capital Markets | Outperform |
| Feb-02-21 | Initiated | Guggenheim | Buy |
| Jun-26-20 | Downgrade | Goldman | Neutral → Sell |
| Nov-20-19 | Initiated | Evercore ISI | Outperform |
| Nov-19-19 | Initiated | Goldman | Neutral |
| Nov-19-19 | Initiated | Jefferies | Buy |
| Nov-19-19 | Initiated | Needham | Buy |
View All
Phathom Pharmaceuticals Inc Stock (PHAT) Latest News
Phathom Pharmaceuticals to Participate in the 23rd Annual Needham Virtual Healthcare Conference
GlobeNewswire Inc.
Phathom Pharmaceuticals Launches Direct-to-Consumer Campaign, “VOQUEZNA Can Kick Some Acid”
GlobeNewswire Inc.
Phathom Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
GlobeNewswire Inc.
Phathom Pharmaceuticals to Report Fourth Quarter and Full Year 2023 Financial Results and Provide Business Update on Thursday, March 7, 2024
GlobeNewswire Inc.
Walmart Posts Upbeat Earnings, Joins Armstrong World Industries, Owens & Minor And Other Big Stocks Moving Higher On Tuesday
Benzinga
Phathom Pharmaceuticals to Present at the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference
GlobeNewswire Inc.
Phathom Pharmaceuticals Inc Stock (PHAT) Financials Data
Phathom Pharmaceuticals Inc (PHAT) Net Income 2024
PHAT net income (TTM) was -$201.59 million for the quarter ending December 31, 2023, a -1.96% decrease year-over-year.
Phathom Pharmaceuticals Inc (PHAT) Cash Flow 2024
PHAT recorded a free cash flow (TTM) of -$139.21 million for the quarter ending December 31, 2023, a +5.66% increase year-over-year.
Phathom Pharmaceuticals Inc (PHAT) Earnings per Share 2024
PHAT earnings per share (TTM) was -$3.94 for the quarter ending December 31, 2023, a +21.98% growth year-over-year.
About Phathom Pharmaceuticals Inc
Phathom Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada to vonoprazan, a potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach. It is also developing vonoprazan, which is in Phase III clinical trials for the treatment of erosive gastroesophageal reflux disease; and in combination with antibiotics for the treatment of Helicobacter pylori infection. The company was incorporated in 2018 and is based in Buffalo Grove, Illinois.
1.53%
3.38%
Cap:
|
Volume (24h):